Przypadki nadmiernej supresji przytarczyc u chorych dializowanych otrzewnowo leczonych cynakalcetem

Abstract

Calcimimetics provide a potential therapeutic benefit through suppressing parathyroid hormone (PTH) re­lease without increasing calcium and phosphorus con­centrations in patients with secondary hyperparathy­roidism. In this report we present one center experience with cinacalcet given to six peritoneal dialysis (PD) pa­tients. We observed 60–80% decrease of the baseline PTH concentration. In four patients we noticed very low PTH level which resulted in discontinuation of cinacal­cet. There are only a few studies concerning calcimi­metics application in PD patients. We would indicate that long-term cinacalcet therapy requires a regular PTH monitoring and very strict sequential dose titration especially in PD patients because of the increased risk of low-turnover bone disease.